SecBot SecBot

XGN

EXAGEN INC.
Nasdaq· Services-Medical Laboratories· Inc. DE· CIK 0001274737 Healthcare & Medical Devices
$7.82 +0.35 (+4.69%)
Oct 27 4:00 PM ET · prev $7.47
Market cap
$176.1M
Micro cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
$11.00
+41% · range $9.00–12.00
Next earnings
Nov 16
in 20 days · EPS est. −$0.17
1 year
−34.3%
from $11.91 · Oct 27
30 days
−7.8%
from $8.48
52-week range
$2.65–11.91
−34% from high · low Mar 30
Avg volume 20D
361.7K
Oct 16 spike 965.8K
Short interest
🔒 Subscribers only
Insider net
−$417.9K
1 buyer · 2 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 16, 2026
Strongest MIXED Exagen Inc. (XGN) saw mixed insider activity: CEO John Aballi sold $270K worth of shares in an open-market…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $104.4K at an average $7.46. 2 insiders sold $522.4K.

  • InstitutionsBEARISH

    Q2 2026: 6 added (0 new), 10 trimmed or exited.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.145 → −$0.170 over 90 days. 0 up, 1 down in 30 days.

  • TrendDOWNTREND

    0% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCADD322,502$1.5M
First Eagle Investment Management, LLCDOUBLED306,965$1.4M
MARSHALL WACE, LLPDOUBLED306,703$1.4M
RTW INVESTMENTS, LPTRIM195,000$906.8K
Man Group plcADD167,292$777.9K
SEI INVESTMENTS COTRIM109,005$506.9K
Squarepoint Ops LLCTRIM108,993$506.8K
GOLDMAN SACHS GROUP INCTRIM52,082$242.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy3Buy8Hold1Sell0Strong Sell0
12-month targets · 7 analysts

Price is below the lowest target. Median implies +41%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 19, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Oct 13, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Aug 5, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Aug 5, 2026B. Riley Securities
REITERATE
REITERATEBuy
Aug 5, 2026BTIG
MAINTAIN
MAINTAINBuy
Jun 25, 2026Roth Capital
INITIATE
INITIATEBuy

Insider ledger

Form 4
$104.4K
bought · 1 insider
$522.4K
sold · 2 insiders
+4.8%
vs their $7.46 cost
DateInsiderTypeValue
Oct 19, 2026
Chernett Jorey
10%+ Owner
BUY$104.4K
Oct 16, 2026
ABALLI JOHN
President and CEO
SELL$269.8K
Sep 1, 2026
Black Jeffrey G.
Chief Financial Officer
SELL$148.8K
Sep 1, 2026
Black Jeffrey G.
Chief Financial Officer
AWARD$4.7K
Jun 9, 2026
Robertson Bruce C
Director
AWARD37,500 sh
Jun 9, 2026
Kim Paul
Director
AWARD37,500 sh
Jun 9, 2026
Stokes Frank
Director
AWARD37,500 sh
Jun 9, 2026
McKhann Chas
Director
AWARD37,500 sh

Earnings setup

Estimates
Nov 16
reports in 20 days
−$0.17
EPS estimate, this quarter
−17%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.17-$0.18–-$0.16+0.0%$18.3M
Next Q-$0.17-$0.18–-$0.17-2.9%$18.3M
Current FY-$0.63-$0.63–-$0.63-1.6%$73.9M
Next FY-$0.47-$0.53–-$0.41+0.0%$81.5M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 SEC
Exagen Inc. (XGN) saw mixed insider activity: CEO John Aballi sold $270K worth of shares in an open-market sale, while…
CLUSTER — Impact 4/10
Oct 19, 2026 Insider
Chernett Jorey bought 14,000 shares
10%+ Owner @ $7.46 ($104.4K)
Oct 16, 2026 Insider
ABALLI JOHN sold 34,294 shares
President and CEO @ $7.87 ($269.8K)
Sep 1, 2026 Insider
Black Jeffrey G. sold 20,614 shares
Chief Financial Officer @ $7.22 ($148.8K)
Aug 4, 2026 SEC
Exagen reported Q2 2026 results with record revenue of $19.9M (+16% YoY), a narrower net loss of -$3.2M (vs -$4.4M a…
8-K — Impact 7/10
Aug 4, 2026 Earnings
Exagen Inc. Reports Second Quarter 2026 Financial Results
Exagen reported Q2'26 financial results, achieving record total revenue, test volume and trailing tw
Jun 30, 2026 Inst.
JANE STREET GROUP, LLC — ADD
322,502 shares ($1.5M)
Jun 30, 2026 Inst.
First Eagle Investment Management, — DOUBLED
306,965 shares ($1.4M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 16, 2026
Earnings date
XGN Q3 2026 Earnings Scheduled — 2026-11-16
Recent
Aug 4, 2026
Earnings
Exagen Inc. Reports Second Quarter 2026 Financial Results
Exagen reported Q2'26 financial results, achieving record total revenue, test volume and trailing twelve-month ASP. Full year revenue guidance…
Aug 4, 2026
Earnings date
XGN Q2 2026 Earnings Scheduled — 2026-08-04
Jul 27, 2026
Earnings date
XGN Q2 2026 Earnings Scheduled — 2026-07-27
May 11, 2026
Earnings
Exagen Inc. Reports First Quarter 2026 Results
Delivers record total revenue and AVISE(R) CTD average selling price Delivers record total revenue and AVISE(R) CTD average selling price
May 11, 2026
Earnings date
XGN Q1 2026 Earnings Scheduled — 2026-05-11

SecBot reports

9 filings · 1 press release · 3 bullish · 4 bearish · 1 mixed · 1 neutral
All XGN filing & press-release reports (10)